Clinical trials: T-Cell Non-Hodgkin Lymphoma
Extranodal NK/T-cell Lymphoma
Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL
The purpose of this multi-center, single arm, phase Ⅱ clinical trail is to evaluate the efficacy and toxicity of concurrent chemoradiotherapy by using single-drug pegaspargase for patients with ENKTL in stage IE to IIE.
- Trial name
- ENKTL (NCT06406556)
- Testing
- Pegaspargase combined with concurrent radiotherapy.
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sun Yat-sen University
EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma
A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies
The present study is a multi-center, single-arm, open, phase I/IIa clinical trial to evaluate the efficacy and safety of EBViNT Cell when administered to patients with Epstein-Barr (EBV) positive malignancies The present study…
- Trial name
- NCT03789617
- Testing
- EBViNT Cell
- Where
- 8 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Eutilex
Lymphoma, Extranodal NK-T-Cell, EBV
Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation
1. To compare the therapeutic effects, safety and the corresponding pharmacokinetics and pharmacodynamics between two different method of drug administration: 10mg, daily and 30mg/d, twice every week, and find out the more effect…
- Trial name
- NCT02878278
- Testing
- Chidamide BIW, Chidamide QD
- Volunteers
- 24 people
- Sponsor
- Huiqiang Huang
Relapse/Refratory Peripheral T Cell Lymphoma
Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma
The purpose of this study is to investigate efficacy and safety of Chidamide Combined With Cyclophosphamide,Prednisone,Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma :a Phase…
- Trial name
- NCT02879526
- Testing
- C-CPT
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
T-Cell Lymphoma, Relapsed T-Cell Lymphoma
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
This is an open-label, single-arm pilot study of Oncaspar® with dexamethasone for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), excluding extranodal NK/T cell lymphoma (ENKTL).
- Conditions
- T-Cell Lymphoma, Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma
- Trial name
- NCT01878708
- Testing
- PEG-L-asparaginase, Dexamethasone acetate
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, B-Cell, CAR-T
C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.
- Trial name
- NCT06210243
- Testing
- C752
- Where
- China
- Volunteers
- 2 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Lymphoma
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
The goal of this clinical research study is to learn if treatment with two types of chemotherapy combinations can help to control peripheral T-cell lymphoma.
- Trial name
- NCT00290433
- Testing
- Cyclophosphamide, Mesna, Vincristine
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
Mature T-Cell and NK-Cell Neoplasm
Copanlisib and Gemcitabine in Relapsed/Refractory PTCL
COPGEM (Copanlisib and Gemcitabine)chemotherapy regimen is proposed as the salvage treatment for relapsed or refractory peripheral T-cell or NK/T-cell lymphomas in this study protocol, which would be expected to be feasible and…
- Trial name
- NCT03052933
- Testing
- Copanlisib, Gemcitabine
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Chonnam National University Hospital
Sezary Syndrome, Pruritus
Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome
The purpose of this randomized, double-blinded, placebo-controlled study is to test the hypothesis that administration of aprepitant will decrease the severity of pruritus in patients with Sèzary Syndrome.
- Trial name
- NCT01625455
- Testing
- Aprepitant
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vanderbilt University Medical Center
Extranodal NK/T-cell Lymphoma, Nasal Type
SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma
This is an open-label, multi-center, nonrandomized, Phase 2 study to evaluate efficacy and safety of SHR-1210 in subjects with relapsed or refractory extranodal NK/T cell lymphoma.Efficacy will be assessed every 8 weeks according…
- Trial name
- NCT03363555
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
B Cell Lymphoma, B Cell Leukemia
CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD19 CARvac in patients with relapsed and/or refractory B cell malignancies.
- Trial name
- NCT04156243
- Testing
- CD19 CARvac T cells
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
Lymphoma
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
RATIONALE: Giving high-dose chemotherapy drugs, such as carmustine, etoposide, and cyclophosphamide, before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00641381
- Testing
- carmustine, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Non-hodgkin's Lymphoma
Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma
To evaluate the safety and efficacy of SL19+22 in patients with relapsed or refractory non-Hodgkin's lymphoma.
- Trial name
- NCT05206071
- Testing
- CD19+22 CAR-T cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Leukemia, Lymphoma
Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy and total body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00028730
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed or Refractory Peripheral T-Cell Lymphoma
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL).
- Trial name
- PTCL (NCT02464228)
- Testing
- Tipifarnib
- Where
- 13 sites in United States, South Korea and 1 more
- Volunteers
- 65 people
- Sponsor
- Kura Oncology, Inc.
Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
This is an open-label, phase I-II dose-escalation and expansion study designed to define the recommended dose of brigatinib as monotherapy in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors and to…
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor
- Trial name
- Briga-PED (NCT04925609)
- Testing
- Brigatinib
- Where
- 2 sites in France, Netherlands
- Volunteers
- 65 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Kidney Cancer, Leukemia
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who…
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00066599
- Testing
- voriconazole
- Where
- 7 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia,B-Cell, Non-hodgkin Lymphoma,B Cell
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for refractory/relapsed B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.
- Trial name
- NCT06346912
- Testing
- CD19-BAFF Targeted CAR T-cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
B-cell Acute Lymphoblastic Leukemia
Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）
The purpose of this study is to evaluate the safety and efficacy of IFN-α combined with CAR-T cell therapy in relapsed and refractory acute lymphoblastic leukemia (R/R ALL).
- Trial name
- NCT04534634
- Testing
- IFN-α combined with CAR-T cell therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Soochow University
HIV Associated Lymphoma
HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903
This is a Phase II multi-center trial single arm trial of autologous transplantation (ASCT) followed by administration of HST-NEETs for treatment of HIV associated lymphoma
- Trial name
- BMTCTN1903 (NCT04975698)
- Testing
- HST-NEETs, Bone Marrow Transplant
- Where
- 11 sites in United States
- Volunteers
- 12 people
- Sponsor
- Catherine Bollard
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.